Edition:
United States

Sanofi SA (SNY)

SNY on New York Consolidated

42.76USD
21 Feb 2017
Change (% chg)

$-0.40 (-0.93%)
Prev Close
$43.16
Open
$42.21
Day's High
$42.78
Day's Low
$42.08
Volume
2,857,519
Avg. Vol
2,166,678
52-wk High
$44.50
52-wk Low
$36.81

Latest Key Developments (Source: Significant Developments)

Ipsen acquires a portfolio of select consumer healthcare products from Sanofi
Monday, 13 Feb 2017 01:52am EST 

Ipsen SA : Ipsen to acquire a portfolio of select consumer healthcare products from Sanofi . Ipsen to pay 83 million euros ($88.24 million) cash upon closing for products . Transaction, which is subject to customary closing conditions, including european commission's approval, is expected to close in Q2 of 2017 .Transaction will be fully financed by Ipsen's existing cash and lines of credit.  Full Article

Regeneron says price increases unrelated from innovation will be pushed back on
Thursday, 9 Feb 2017 09:00am EST 

Regeneron Pharmaceuticals Inc - : Regeneron CEO: "As we further diversify our product related revenue stream, we do not plan to provide eylea guidance after 2017" . Regeneron CEO says Amgen's asserted patent claims on repatha are invalid and we look forward to pursuing our appeal over the coming months: conf call . Regeneron's Bob Terifay says Eylea will continue for co over the years to come . Regeneron: Eylea sales growth has slowed reflecting normal market dynamics for the product that has been around for over 5 yrs with no price hike since launch . Regeneron CEO says changes in pharmaceutical drug pricing will need congressional action . Regeneron CEO "Price increases that are unrelated or uncoupled from innovation will be pushed back on" . Regeneron CEO: Constant price increases & magnitude of them are reflection of tone deafness on those taking hikes & complexities about how rebates work . Regeneron CEO: "There is an opportunity to come up with more responsible pricing", in relation to rheumatoid arthritis drug, sarilumab . Regeneron CEO: "Pharma is running around saying the middleman (PBM) is taking too much; the middleman says prices are too high and patients are wondering what is really going on" . Regeneron CEO: "price increases are nice but if you cannot get them you better be able to innovate and that is our sweet spot" Further company coverage: [AMGN.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Regeneron posts Q4 adj. profit $3.04/shr
Thursday, 9 Feb 2017 06:32am EST 

Regeneron Pharmaceuticals Inc : Regeneron reports fourth quarter and full year 2016 financial and operating results . Regeneron Pharmaceuticals Inc - Q4 2016 eylea global net sales increased 17 pct to $1.35 billion versus Q4 2015 . Regeneron Pharmaceuticals Inc - in Q4 of 2016, global net sales of praluent were $41 million, compared to $7 million in Q4 of 2015 . Says net product sales were $863 million in Q4, compared to $750 million . Regeneron Pharmaceuticals Inc - total revenues increased by 12 pct to $1.227 billion in Q4 of 2016 . Regeneron Pharmaceuticals Inc - sees 2017 Sanofi reimbursement of Regeneron commercialization-related expenses of $400 million - $450 million . Regeneron Pharmaceuticals Inc qtrly non-GAAP net income per share $3.04 . Qtrly GAAP net income per share $2.19 . Q4 earnings per share view $3.03, revenue view $1.30 billion -- Thomson Reuters I/B/E/S . Regeneron Pharmaceuticals Inc - sees single digit percentage growth over 2016 for eylea U.S. net product sales in 2017 . Regeneron Pharmaceuticals Inc - "also studying dupixent in patients with nasal polyps and pediatric patients with asthma or atopic dermatitis" . Regeneron - dupixent may have potential to help additional patients with serious allergic diseases, Phase 3 data in adult asthma patients expected later this year . Regeneron Pharmaceuticals Inc - pre-approval inspection for dupixent has been scheduled for Q1 of 2017.  Full Article

Regeneron pharmaceuticals says appeals court grants stay of permanent injunction for praluent
Wednesday, 8 Feb 2017 05:30pm EST 

Regeneron Pharmaceuticals Inc : Regeneron Pharmaceuticals Inc says appeals court grants stay of permanent injunction for praluent (alirocumab) during appeals process . Regeneron -Sanofi and Regeneron will continue marketing, selling and manufacturing praluent in U.S. during appeal process . Regeneron Pharmaceuticals Inc - injunction is not applicable outside U.S. or to clinical trials which are continuing as planned .Regeneron Pharmaceuticals Inc - anticipated launch of praluent in 15 additional countries in 2017.  Full Article

Sanofi's Xyzal® Allergy 24HR approved for over-the-counter use in United States
Wednesday, 1 Feb 2017 01:35am EST 

Sanofi : Says U.S. Food and Drug Administration (FDA) approved Xyzal(®) Allergy 24HR as an over-the-counter (OTC) treatment for the relief of symptoms associated with seasonal and year-round allergies .Two formulations of Xyzal are now approved for OTC use - 5 mg tablets for ages 6 years and older, as well as 0.5 mg/mL oral solution for ages 2 years and older.  Full Article

Sanofi buys 87,298 shares of Regeneron's common stock on Jan 11
Friday, 13 Jan 2017 04:28pm EST 

:Sanofi reports open market purchase of 87,298 shares of Regeneron Pharmaceuticals Inc's common stock on Jan 11 - SEC filing.  Full Article

Amgen comments on Delaware court's ruling on PCSK9 patent litigation
Monday, 9 Jan 2017 08:04pm EST 

Amgen Inc : Amgen statement on January 9, 2017, U.S. District court decision . Amgen Inc - U.S. District court of Delaware denied Sanofi and Regeneron's motion to stay injunction pending appeal in ongoing PCSK9 patent litigation .Amgen Inc says by ruling, court has extended time before injunction will be imposed by 15 days (from 30 days to 45 days).  Full Article

Regeneron says Sanofi plant used to fill drugs now deemed acceptable
Monday, 9 Jan 2017 07:26pm EST 

Regeneron Pharmaceuticals Inc : Regeneron CEO says Sanofi plant that will fill atopic dermatitis drug awaiting U.S. approval decision deemed acceptable . Regeneron CEO predicts PBMs will pay for Dupixent atopic dermatitis drug once approved . Regeneron ceo says expects to file for U.S. approval of dupilumab for asthma in Q4 . Regeneron sees 2017 reimbursement of commercialization expenses from Sanofi of $400 million to $450 million .Regeneron sees 2017 capital expenditures $375 million to $450 million.  Full Article

Regeneron says Sanofi plant used to fill drugs now deemed acceptable
Monday, 9 Jan 2017 06:49pm EST 

Regeneron Pharmaceuticals Inc : Regeneron CEO says Sanofi plant that will fill atopic dermatitis drug awaiting U.S. approval decision deemed acceptable . Regeneron CEO predicts PBMs will pay for Dupixent atopic dermatitis drug once approved . Regeneron ceo says expects to file for U.S. approval of dupilumab for asthma in Q4 . Regeneron sees 2017 reimbursement of commercialization expenses from Sanofi of $400 million to $450 million .Regeneron sees 2017 capital expenditures $375 million to $450 million.  Full Article

Amgen comments on Delaware court's ruling on PCSK9 patent litigation
Monday, 9 Jan 2017 06:21pm EST 

Amgen Inc : Amgen statement on January 9, 2017, U.S. District court decision . Amgen Inc - U.S. District court of Delaware denied Sanofi and Regeneron's motion to stay injunction pending appeal in ongoing PCSK9 patent litigation .Amgen Inc says by ruling, court has extended time before injunction will be imposed by 15 days (from 30 days to 45 days).  Full Article

More From Around the Web

Photo

How Sanofi lost out to J&J in $30 billion battle for Actelion

ZURICH Swiss biotech company Actelion , days before agreeing to a $30 billion bid by Johnson & Johnson , found a rival offer to be as attractive but went with J&J because its offer provided more certainty, a filing showed on Thursday.